StreetAlpha.app
Home › Stocks › CELC

Celcuity Inc. (CELC)

Healthcare
$58.01
▼ −4.23%
LAST CLOSE · NOV 17

Celcuity is a Minneapolis biotechnology company developing gedatolisib, a cancer drug candidate for breast and prostate cancer patients. It last closed at $58.01 on Nov 17, down 4.23% on the day. CELC last reported earnings on Thu, Aug 13, 2026. The average 12-month price target from 6 analysts is $149.17 (+157.1% from the last close), with a high of $169.00 and a low of $134.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in CELC, 50% of them bullish and 50% bearish.

AI Auto Pilots
Is CELC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$256.0M
EPS (diluted)
−$4.72
Free cash flow
−$213.5M
Valuation
Market cap
$2.8B
49.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$178.2M
At Sep 30
Debt
$0
At Sep 30
Shareholder equity
−$74.0M
Shares outstanding
49.1M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$29.6M−$29.6MFY2021FY2022: −$40.4M−$40.4MFY2022FY2023: −$63.8M−$63.8MFY2023FY2024: −$111.8M−$111.8MFY2024FY2025: −$177.0M−$177.0MFY2025

From CELC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Aug 13
2026 · After the close (AMC)
Reported EPS
-$1.44
vs -$1.08 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
±7.9%
Priced in before that report
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on CELC in the past 90 days
Average 12-month target
$149.17
▲ 157.1% upside

Based on 6 analysts who set a price target on CELC in the past 90 days. The average target is $149.17, with a high of $169.00 and a low of $134.00, compared with the last close of $58.01.

Low $134.00Avg $149.17High $169.00
Blue marker: last close $58.01
Highest target$169.00
Average target$149.17
Lowest target$134.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 9Buy$155 → $150
GuggenheimMaintained
Nov 6Buy$169
Cantor FitzgeraldInitiated
Oct 22Buy$140
TD CowenReiterated
Oct 21Buy$145
NeedhamTarget lowered
Sep 30Buy$140 → $134
DateFirmActionRatingPrice target
Nov 9HC Wainwright & Co.Target loweredBuy$155 → $150
Nov 6GuggenheimMaintainedBuy$169
Oct 22Cantor FitzgeraldInitiatedBuy$140
Oct 21TD CowenReiteratedBuy$145
Sep 30NeedhamTarget loweredBuy$140 → $134
Loading…

Technical Analysis

CELC · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 14% below its 20 day and 23% below its 50 day average. It is 69% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot S1 at $56.11, and the nearest resistance the Pivot at $58.54.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.3%/day
Key levels
$151.0252 week high+160.3%
$97.94200 day average+68.8%
$82.67100 day average+42.5%
$72.24Swing high (Nov 9)+24.5%
$71.0750 day average+22.5%
$65.9920 day average+13.8%
$60.44Pivot R1+4.2%
$58.54Pivot+0.9%
$58.01Last close
$56.11Pivot S1−3.3%
$53.5452 week low−7.7%
$53.54Swing low (Oct 16)−7.7%
Indicators
RSI (14)34.46Weak, oversold below 30Neutral
MACD-2.31Below its signal lineBearish
Stochastic12.4Near the bottom of its rangeOversold
ADX (14)18.5No clear trend
Williams %R-91.8Oversold below −80, overbought above −20Oversold
CCI (20)-197.3Oversold below −100, overbought above 100Oversold
Rate of change−16.8%Change over 10 sessionsBearish
ATR (14)$4.24Typical daily range, 7.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CELC

What happened before

See how CELC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CELC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CELC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Aug 26 – Oct 8
Loading…

See today’s whale options flow across the market →

CELC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲161 buying vs 130 selling
  • ▲Held by funds +1.8 pts
  • ▼Funds holding -7
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding270277−2.5%
In funds' top 101314−7.1%
Held by funds117.9%116.1%+1.8 pts
New / increased50 / 11160 / 108−4.2%
Reduced / sold out74 / 5680 / 63−9.1%
Put/call ratio0.543.70−85.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CELC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CELC is in one of them and how their past CELC trades turned out.

CELC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CELC in an article yet. Here's the latest on the wider market.

CELC Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jun 23
Who traded CELC · since 2020
Latest 2 filings
$1K – $15KTraded May 26, 2021Filed Jun 23, 2021
$1K – $15KTraded Jun 18, 2020Filed Mar 5, 2021
PersonTypeAmountTradedFiledDelay
Tom MalinowskiD · NJSell$1K – $15KMay 26, 2021Jun 23, 202128 d
Tom MalinowskiD · NJBuy$1K – $15KJun 18, 2020Mar 5, 2021260 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Celcuity

Celcuity is a biotechnology company based in Minneapolis, Minnesota, that is developing gedatolisib, an investigational cancer treatment for solid tumors. The drug is given intravenously and works by blocking several parts of the PI3K, AKT and mTOR signaling pathway that tumors use to grow and survive. The company's main studies focus on advanced breast cancer and metastatic prostate cancer, and its drug is still in clinical trials and under regulatory review.

Headquarters
Minneapolis, MN